Search the Newsreel

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Niagen Bioscience has partnered with Evotec to advance the preclinical development of NB4168, their lead investigational candidate for rare pediatric diseases, particularly Ataxia Telangiectasia (A-T). Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies at their Verona campus, utilizing their INDiGO platform to accelerate the …

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts

Analysts have issued a consensus rating of "Moderate Buy" for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), with 14 out of 18 analysts recommending the stock. The average 12-month price target is $57.82, significantly above the recent trading price of $25.82. The company recently reported better-than-expected quarterly …

Is Niagen Bioscience (NAGE) Quietly Recasting Its Brand Around E‑Commerce Scale And Clinical Proof

The Agency Group Australia Addresses ASX Price and Volume Inquiry Amid Aura Group Transaction Talks

Qiagen (QGEN) Stock Faces An Execution Puzzle After Margin Rebound

Agenus (AGEN) Earnings Date and Reports 2026

Hangzhou Diagens Biotechnology Announces Unaudited Interim Results for First Half of 2026

Vistagen (Nasdaq: VTGN) posts Phase 2 fasedienol efficacy signals

Vistagen Therapeutics, Inc. announced topline results from an exploratory Phase 2 study of intranasal fasedienol for social anxiety disorder. The study met its safety objective and showed efficacy signals, particularly in patients with very severe social anxiety, which will inform discussions with the FDA …

The Agency Group Australia Confirms Confidential Scrip-for-Scrip Merger Offer from Aura Group at $0.04 Per Share

Agenus earnings missed by $0.02, revenue was in line with estimates

Niagen Bioscience launches Tru Niagen on Walmart.com

Niagen Bioscience has launched its Tru Niagen NAD+ supplement on Walmart.com, making its healthy-aging product more widely available. The initial offering includes 300 mg bottles, with more products to follow. Tru Niagen, which contains patented nicotinamide riboside, is backed by numerous human clinical studies …

VistaGen Granted Nasdaq Extension to Regain Bid Compliance

VistaGen Therapeutics has received a 180-day extension from Nasdaq, lasting until February 1, 2027, to meet the $1.00 minimum bid price requirement for its common stock. Failure to comply within this period could lead to delisting. Analysts currently rate VTGN as a Hold with …

Sei Investments Co. Increases Holdings in Niagen Bioscience, Inc. $NAGE

Sei Investments Co. significantly increased its stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) by 155.6% in the first quarter, now owning 971,574 shares valued at $4.29 million. Despite this increased institutional interest, Niagen Bioscience shares opened down 14.7% near their 52-week low, with quarterly earnings …

Qiagen N.V. : Jefferies reiterates its Buy rating

Jefferies has reiterated its "Buy" rating for Qiagen N.V., reflecting a positive outlook on the stock. This comes as Qiagen's Q2 earnings exceeded expectations, though the company has maintained its guidance, similar to its peers. The article also provides a brief company profile, financial …

Qiagen NV (0RLT) Q4 2024 Earnings Report - Results, Call & Slides

Qiagen NV (0RLT) reported its Q4 2024 earnings, with an actual EPS of €0.56 matching the consensus but missing by less than €0.01 against expectations. The company's revenue for Q4 2024 was €452.34M, slightly beating the expected €452.21M. Qiagen also provided details for its …

Adagene Inc (ADAG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Adagene Inc (ADAG), highlighting analyst ratings and price targets. Based on 7 analysts, the stock has a "Buy" consensus with a target price of USD 7.00, representing a 159.46% upside. The report includes current stock price, market …

Qiagen N.V. 2026 Q2 - Results - Earnings Call Presentation (NYSE:QGEN) 2026-08-06

Is Agenus Inc (AGEN) Overvalued After Q2 Earnings Beat? Q2 EPS: $0.06, Revenue: $34.5M; GF Score: 40/100

Vistagen's second fasedienol dose showed no new safety findings

Vistagen (Nasdaq: VTGN) announced topline results from an exploratory Phase 2 study of intranasal fasedienol for social anxiety disorder, showing repeat dosing was safe and well-tolerated with no new safety findings. While overall statistical significance was not met for primary efficacy endpoints, nominally significant …

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN) announced topline results from an exploratory Phase 2 repeat dose study of fasedienol nasal spray for social anxiety disorder. The study showed favorable safety and tolerability, with efficacy signals observed across primary and secondary endpoints, particularly in patients with very severe …

QIAGEN NV : Deutsche Bank maintains a Buy rating

Deutsche Bank has reiterated its Buy rating for QIAGEN NV, with analyst Jan Koch maintaining a positive outlook on the stock. This comes amidst recent news that Jefferies also reiterated a Buy rating for QIAGEN and that the company's Q2 earnings were ahead of …

Agenus Inc (AGEN) News, Articles, Events & Latest Updates

This article provides recent news and updates for Agenus Inc. (AGEN), an immuno-oncology company. Key highlights include the company's Q2 2026 earnings report, advancements in its Phase 3 ROBBIN trial, presentations at ESMO 2026, and securing $340 million in financing to support its strategic …

Niagen Bioscience, Inc. $NAGE Holdings Boosted by Renaissance Technologies LLC

ImageneBio (IMA) files to register 5.77M warrant shares for investor resale

ImageneBio (IMA) has filed an S-3 registration statement to allow for the resale of up to 5.77 million shares of common stock by existing selling stockholders. These shares are issuable upon the exercise of pre-funded warrants that were part of a private placement on …

Agenus Inc. (NASDAQ: AGEN) posts Q2 2026 revenue, secures $85M placement

Niagen Bioscience (NAGE) Stock Sinks As Profit Cushion Thins

HC Wainwright Predicts Weaker Earnings for Niagen Bioscience

Ultragenyx (RARE) Stock Revenue Record Clashes With Ongoing Cash Burn

Niagen Bioscience, Inc. Stock 12‑Month Price Target Cut to $12.08, Implies 248% Upside

Niagen Bioscience, Inc.'s average stock price target has been reduced slightly from $12.42 to $12.08 by 6 analysts, with forecasts ranging from $8.5 to $22 per share. Despite the cut, the updated target suggests a 248% potential upside based on the August 4th closing …

Qiagen übertrifft Erwartungen und bestätigt Prognose

Agenus advances Phase 3 ROBBIN trial of botensilimab-balstilimab in neoadjuvant MSS colon cancer

Agenus is moving forward with its Phase 3 ROBBIN trial for botensilimab and balstilimab in high-risk Stage II-III MSS colon cancer, with the first patient dosing expected in Q1 2027. This advancement follows positive results from earlier trials, NEST and UNICORN, which demonstrated significant …

Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, Qiagen (QGEN) reported revenue of $535.04 million, up 0.3% over the same period last year. EPS came in at $0.62, compared to $0.63 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $527.94 …

Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value

Niagen Bioscience (NAGE) is gaining attention after a new study linked its Niagen nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration. Despite recent stock price declines, the company's valuation is seen as undervalued at $2.96 compared to a fair value of $12.60, driven …

Vistagen Therapeutics (NASDAQ: VTGN) granted 180-day Nasdaq bid-price extension

Vistagen Therapeutics (NASDAQ: VTGN) has received a 180-day extension from Nasdaq, until February 1, 2027, to regain compliance with the $1.00 per share minimum bid price requirement. The company's common stock listing remains effective, and Vistagen intends to cure the deficiency within this period …

Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Vistagen Therapeutics (VTGN) announced it received an extension from Nasdaq until February 1, 2027, to meet the $1.00 minimum bid price requirement. The company's listing remains active during this period, but failure to comply could lead to delisting. This information is based on an …

Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates

Qiagen (QGEN) exceeded Q2 earnings and revenue estimates, reporting $0.62 per share against a $0.60 consensus and revenues of $535.04 million, surpassing the $527.91 million estimate. Despite the beat, the company's shares have underperformed the S&P 500 year-to-date, and its Zacks Rank of #4 …